was abandoned in late-stage development in 2017 after five deaths in its clinical trial programme related to severely low white blood cells (agranulocytosis) and sepsis. Exscientia said it had ...

Patients can be maintained in the long term on low-dose ATD, but there is still the very small risk of agranulocytosis and, as alluded to above, relapse can still occur on stopping. Many young people ...